|Therapeutic Class:||Miscellaneous Antibiotics|
|Manufacturer:||Acme Laboratories Limited.|
|Last Updated:||2020-11-21 18:15:00|
Aximin Tablet contains Rifaximin. Aximin uses:
Acute infectious diarrhoea including travelers diarrhoea, Diarrhoea predominant Irritable Bowel Syndrome (IBS-D), Hepatic Encephalopathy (H.E.)
Aximin Tablet contains Rifaximin 550 mg. Aximin doses:
Acute Infectious Diarrhoea including Travelers’ Diarrhoea: 200 mg three times daily for 3 days.
Diarrhoea predominant Irritable Bowel Syndrome (IBS-D): 550 mg three times daily for 14 days.
Hepatic Encephalopathy (H.E.): 550 mg twice daily
Common side effects are nausea, vomiting, abdominal pain, flatulence, headache and dizziness.
Rifaximin is a non-aminoglycoside semi-synthetic antibacterial derived from rifamycin SV. It inhibits bacterial RNA synthesis by binding to the bacterial DNA-dependent RNA polymerase and has antibacterial activity against Escherichia coli (E. coli).
Pregnancy and lactation. Caution in severe hepatic impairment (Child-Pugh class C). Not effective against diarrhoea caused by pathogen other than E. coli ; or diarrhoea complicated by fever and/or blood in the stool. Prolonged use may result in Clotridum difficile-associated diarrhoea. Severe hepatic impairment (Child-pugh class C).
Although In vitro studies demonstrated the potential of Rifaximin to interact with cytochrome P450 (CYP3A4), a clinical drug-drug interaction study demonstrated that Rifaximin did not significantly affect the pharmacokinetics of midazolam. An additional clinical drug-drug interaction study showed no effect of Rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P450 isozymes are not expected.
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Rifaximin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Use in Lactation: It is not known whether Rifaximin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from Rifaximin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Rifaximin is contraindicated in patients with a hypersensitivity to Rifaximin, or any of the Rifamycin antimicrobial agents, or any of the components of this preparation.
Use in Children: The safety and effectiveness of Rifaximin 200 mg in pediatric patients with travelers’ diarrhoea less than 12 years of age have not established.The safety and effectiveness of Rifaximin 550 mg for hepatic encephalopathy have not been established in patients <18 years of age.
Use in geriatric patients: Clinical studies of Rifaximin tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.
Use in Renal Insufficient Patients:The pharmacokinetics of Rifaximin in patients with impaired renal function has not been studied.
Use in Hepatic Insufficient Patients:No dosage adjustment with Rifaximin is necessary due to its limited systemic absorption. Nonetheless, caution should be exercised when Rifaximin is administered to patients with severe hepatic impairment.
No specific information is available on the treatment of over dosage with Rifaximin. In case of over dosage, discontinue Rifaximin, treat symptomatically and institute supportive measures as required.
Store at 20-25° C; excursions permitted to 15-30° C.
Aximin Tablet price in Bangladesh 63.18